

WHAT IS CLAIMED IS:

Sub A1
John P.

1. A composition comprising:

an alpha-2-adrenergic agonist, and
a fatty acid component,

the fatty acid component forms a complex with the
alpha-2-adrenergic agonist; the complex remaining
substantially intact in an aqueous environment.

2. A composition of claim 1 wherein the fatty
acid component is present in an amount effective to
enhance the efficacy of the agonist relative to the
efficacy of the alpha-2-adrenergic agonist without the
fatty acid component.

3. A composition of claim 1 wherein the agonist
comprises a quinoxaline component.

Sub C2
John P.

4. A composition of claim 3 wherein the
quinoxaline component is selected from the group
consisting of quinoxaline, (2-imidazolin-2-ylamino)
quinoxaline, 5-bromo-6-(2-imidazolin-2-ylamino)
quinoxaline, and derivatives thereof and mixtures
thereof.

5. A composition of claim 1 wherein the fatty
acid component is selected from the group consisting of
saturated fatty acids and unsaturated fatty acids,
derivatives thereof and mixtures thereof.

6. A composition of claim 1 wherein the fatty
acid component is selected from the group consisting of
fatty acids having about 12 to about 26 carbon atoms
per molecule, derivatives thereof and mixtures thereof.

[Signature]

7. A composition of claim 1 wherein the fatty acid component is selected from the group consisting of docosahexanoic acids, derivatives thereof and mixtures thereof.

8. A composition of claim 1 wherein the fatty acid component is selected from the group consisting of linolenic acids, derivatives thereof and mixtures thereof.

9. A composition of claim 1 wherein the fatty acid component has a therapeutic effect.

10. A composition of claim 1 wherein the fatty acid component has a therapeutic effect while being in a complex with the agonist.

11. A composition of claim 1 wherein the fatty acid component has a therapeutic effect while not being in a complex with the agonist.

12. A composition of claim 1 wherein the fatty acid component is effective to reduce intraocular pressure when it is administered to the eye.

13. A composition of claim 1 wherein the fatty acid component is selected from the group consisting of prostaglandins, derivatives thereof and mixtures thereof.

14. A composition of claim 1 wherein the fatty acid component is present in an amount effective to enhance the movement of the alpha-2-adrenergic agonist across a lipid membrane.

[Signature]

15. A composition of claim 1 wherein the fatty acid component enhances the movement of the agonist component across a biological membrane under physiological conditions.

16. A composition of claim 1 wherein the fatty acid component is effective to enhance the therapeutic effect provided by the agonist.

17. A composition of claim 1 wherein the complex is able to disassociate in a biological environment.

18. A composition of claim 1 which includes at least one additional agonist and the fatty acid is complexed with both the agonist and the additional agonist.

19. A composition of claim 1 which includes at least one additional fatty acid component and the agonist is complexed with both the fatty acid component and the additional fatty acid component.

20. A composition of claim 1 which is ophthalmically acceptable.

21. A composition of claim 1 which further comprises a carrier.

22. A composition of claim 1 wherein the agonist comprises 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline; and

the fatty acid component is selected from the group consisting of docosahexanoic acids, linolenic

D-2910

acids, prostanoids, derivatives thereof and mixtures thereof.

Sub A2
23. A composition comprising:

a 5-bromo-6-(2-imidazolin-2-ylamino) quinoxa-line; and

a linolenic acid component,
wherein the 5-bromo-6-(2-imidazolin-2-ylamino) quinoxa-line forms a complex with the linoleic acid component,
the complex substantially remains intact in an aqueous environment.